Tag Archives: hepatitis research

Research Use Only Notice: Thymosin Alpha-1 discussed in this article as a research compound is intended for in-vitro and animal research applications only. While Thymosin Alpha-1 has been approved for human therapeutic use in over 35 countries, it is not FDA-approved in the United States. Nothing in this article constitutes medical advice or guidance for human consumption.

Thymosin Alpha-1 — also written Tα1 — is a 28-amino-acid peptide derived from the thymus gland that has become one of the most clinically researched immune-modulating compounds in modern peptide science. Originally isolated from thymic tissue in the 1970s, Thymosin Alpha-1 is approved for therapeutic use in over 35 countries internationally for indications including hepatitis B, hepatitis C, immune reconstitution, and as an adjuvant in some cancer protocols. In the United States, it remains a research-grade compound under research-use-only labeling. This complete guide from the chemistry team at OPS Peptide Science walks through what Thymosin Alpha-1 is, how it modulates immune function, and where it sits in the broader research catalog.

For the foundational research-workflow protocols, see our companion guides on how to reconstitute peptides, how to inject peptides, and peptide storage and refrigeration.

What Is Thymosin Alpha-1?

Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide originally isolated from bovine thymus extracts and now produced synthetically. The thymus gland is the organ where T-cells mature, and Thymosin Alpha-1 is one of several thymic peptides involved in this process. Of the various thymic peptides identified in early research, Tα1 has become by far the most studied and the most clinically applied.

Key facts about Thymosin Alpha-1:

• Chemical class — 28-amino-acid synthetic peptide derived from prothymosin alpha
• Molecular weight — approximately 3108 Da
• Sequence — Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN (N-terminally acetylated)
• Half-life — approximately 2 hours
• Form — typically supplied as lyophilized powder; reconstituted with bacteriostatic water
• International brand name — Zadaxin (in countries where it is therapeutically approved)
• Approved use in — 35+ countries internationally; not FDA-approved in the United States

Thymosin Alpha-1’s unusual regulatory position — therapeutically approved in dozens of countries but not in the US — gives the compound a uniquely robust clinical research base. Tens of thousands of patients have received Thymosin Alpha-1 in clinical settings worldwide, producing more documented human research data than most non-FDA-approved peptides in the research catalog.

Thymosin Alpha-1 Structure and Chemistry

Thymosin Alpha-1’s structure reflects its natural origin from prothymosin alpha (ProTα), a longer 113-amino-acid precursor protein. Key structural features:

• Acetylated N-terminus — the N-terminal serine carries an acetyl modification, naturally present in mammalian-produced Tα1 and reproduced in synthetic versions
• Highly conserved across species — the Tα1 sequence is identical in human, bovine, rat, and most mammalian sources
• Acidic character — high content of glutamic and aspartic acid residues gives the peptide a strong negative charge at physiological pH
• No disulfide bonds or complex modifications — relatively straightforward synthesis compared to many research peptides

The structural conservation across species is part of why Tα1 research data translates relatively well between animal models and human applications — the molecule is essentially identical across organisms.

How Thymosin Alpha-1 Works in Research (Mechanism)

The Thymosin Alpha-1 mechanism involves multiple immune system pathways. Research has documented effects on several immune cell types:

• T-cell maturation enhancement — promotes maturation of T-cell precursors in research models, particularly relevant in immunosenescence and post-immunosuppression research
• Dendritic cell modulation — affects dendritic cell function and antigen presentation, key steps in initiating adaptive immune responses
• Toll-Like Receptor (TLR) signaling — binds and modulates TLR2 and TLR9 signaling pathways, influencing innate immune responses
• Th1/Th2 balance modulation — promotes Th1-skewed responses in research models, useful for studies of cellular immunity
• NK cell activity enhancement — research has documented increased natural killer cell activity
• Cytokine modulation — measurable effects on IFN-γ, IL-2, and other immune signaling molecules

Unlike many research peptides with single-pathway mechanisms, Thymosin Alpha-1 acts as a broad immune modulator — engaging multiple receptors and immune cell types to support coordinated immune function. This multi-pathway activity is part of why the compound has applications across so many research areas (hepatitis, sepsis, vaccine adjuvant, post-chemotherapy immune recovery). The published Thymosin Alpha-1 immune research literature on PubMed documents these mechanisms across thousands of studies.

Thymosin Alpha-1 Research Applications

Hepatitis Research

The largest body of Thymosin Alpha-1 clinical research focuses on hepatitis B and hepatitis C — both viral infections where the immune response to the virus determines outcomes. Tα1 has been studied in hundreds of clinical trials in international research, often combined with interferon-based therapies. This research base is what drove the compound’s therapeutic approval in countries with significant hepatitis burden.

Sepsis Research

Severe sepsis research has used Thymosin Alpha-1 to study immune dysregulation contributions to sepsis outcomes. Research has measured Tα1 effects on T-cell function, cytokine profiles, and survival markers in sepsis research models.

Cancer Adjuvant Research

Tα1 has been studied as an adjuvant in research investigating immune support during chemotherapy. The research focus is on immune reconstitution following chemotherapy-induced immunosuppression — measuring T-cell recovery, vaccination response, and infection susceptibility endpoints.

Vaccine Adjuvant Research

Tα1 enhances vaccine responses in research subjects with weakened immune systems. Research has documented improved vaccine seroconversion rates and antibody titer durability when Tα1 is co-administered with vaccines, particularly in elderly research populations and post-transplant patients.

Immune Recovery Research

Research on immune recovery following immunosuppression — whether from disease, medication, or surgical procedures — has used Tα1 to measure restoration of T-cell function and innate immune capacity. This research extends into aging-related immune decline (immunosenescence) and immune recovery in aging research models.

Infectious Disease Research

Beyond hepatitis, Tα1 research extends into broader infectious disease applications — from chronic viral infections to severe respiratory infection research. The immune-modulating mechanism has broad relevance across infection biology.

International Approval Status: A Unique Position

Thymosin Alpha-1’s regulatory status is unusual among research peptides. The compound is therapeutically approved for human use in over 35 countries — including China, Italy, South Korea, and many others — typically for hepatitis B and hepatitis C indications. This international approval base means:

• Decades of clinical safety data — extensive post-marketing surveillance from approved uses
• Established dosing protocols — international research has refined dosing patterns across multiple indications
• Long-term tolerability documentation — broader data than most research-only peptides
• Production scaled to pharmaceutical standards — synthesis protocols are well-established because of the therapeutic market

The compound has been included in the WHO essential medicines considerations for specific indications in some regions. Despite this international history, Thymosin Alpha-1 has not pursued or completed FDA approval in the United States. In the US, it remains a research chemical sold under research-use-only labeling.

Thymosin Alpha-1 Dosing in Research Models

Thymosin Alpha-1 dosing in published research follows patterns established by the international clinical experience:

• Subcutaneous administration — standard route in both research and clinical contexts
• Twice-weekly dosing — common protocol in chronic hepatitis research
• Daily dosing — used in acute research applications and sepsis research
• Cycle-based protocols — some research designs use 6-month cycles followed by evaluation periods
• Dose amounts — typically 0.8-1.6 mg per dose in clinical research; animal research uses mg/kg dose ranges

The well-established dosing protocols from international clinical experience provide a stronger methodological foundation than is available for most non-FDA-approved peptides. Research protocols can reference both pre-clinical and clinical literature. For effect-timeline context, see our guide on how long does it take for peptides to work.

Storage and Stability

Thymosin Alpha-1 stability follows standard medium-sized peptide patterns:

Storage Condition	Form	Stability Window
-80°C	Lyophilized powder	3-5+ years
-20°C	Lyophilized powder	18-24 months
2-8°C	Lyophilized powder	6-12 months
2-8°C	Reconstituted in BAC water	21-28 days
Room temperature	Lyophilized powder	2-4 weeks for transit

For practical storage protocols, see our companion guide on how long do peptides last at room temperature.

How to Identify Quality Research-Grade Thymosin Alpha-1

Quality criteria for research-grade Thymosin Alpha-1:

• 99%+ HPLC-MS verified purity — synthesis of 28-amino-acid acetylated peptides requires careful purification
• Per-lot Certificate of Analysis — each batch independently tested with full chromatographic profile
• Mass spectrometry identity confirmation — confirms molecular weight matches Thymosin Alpha-1 (~3108 Da)
• N-terminal acetylation verification — confirms the natural N-acetyl modification is present
• Chain-of-custody documentation — traceable from manufacturer through fulfillment
• Properly lyophilized appearance — clean white cake at the bottom of the vial
• Research-use-only labeling — required by US regulations

At OPS Peptide Science, every Thymosin Alpha-1 vial ships with a unique BIOVIRIDIAN COA code. Customers can verify the Certificate of Analysis for their specific lot — confirming purity, identity, and N-terminal acetylation before opening the vial.

Regulatory Status

• Approved for therapeutic use in 35+ countries — hepatitis B and C primary indications, with broader regional approvals
• Not FDA-approved in the United States — no equivalent prescription pathway in the US
• Legal as research chemical in the US — sold under research-use-only labeling for in-vitro and animal research
• Not WADA-prohibited as of current updates
• Not DEA-scheduled — no controlled substance status

The contrast between international therapeutic approval and US research-only status is a fundamental feature of Thymosin Alpha-1 regulation. For the complete legal framework around research peptides, see our detailed guide on are peptides illegal.

FAQ

What is Thymosin Alpha-1?

Thymosin Alpha-1 (Tα1) is a 28-amino-acid synthetic peptide derived from thymus tissue. It is an immune-modulating compound studied across hepatitis, sepsis, cancer adjuvant, and immune recovery research. The compound is therapeutically approved for human use in over 35 countries internationally, though not in the United States.

Is Thymosin Alpha-1 the same as Zadaxin?

Zadaxin is the brand name under which Thymosin Alpha-1 is sold therapeutically in countries where it has approval. The molecule is the same. In the US, Thymosin Alpha-1 is sold as a research chemical under research-use-only labeling rather than as a pharmaceutical product.

Is Thymosin Alpha-1 FDA-approved?

No. Despite being approved in 35+ countries internationally for therapeutic use, Thymosin Alpha-1 has not pursued FDA approval in the United States. In the US, it is sold legally as a research chemical for in-vitro and animal research under research-use-only labeling.

How does Thymosin Alpha-1 affect the immune system?

Thymosin Alpha-1 affects multiple immune cell types: it enhances T-cell maturation, modulates dendritic cell function, engages Toll-Like Receptor signaling, promotes Th1-biased responses, and enhances NK cell activity. The combined effect supports coordinated immune function in research models, particularly relevant in immunosuppression recovery and chronic infection contexts.

What’s the half-life of Thymosin Alpha-1?

Approximately 2 hours, which is why research dosing protocols typically use multiple-times-weekly or daily administration rather than less frequent dosing. The short half-life is balanced by sustained downstream effects on immune cell populations that persist beyond the plasma clearance of the peptide itself.

Can Thymosin Alpha-1 be combined with other research peptides?

Yes — Thymosin Alpha-1 is studied in combination with other immune-active research peptides in some protocols. Its multi-pathway mechanism means it generally combines well without obvious pharmacological conflicts. Specific combination research should be informed by published methodology references.

Where can I buy research-grade Thymosin Alpha-1?

Research-grade Thymosin Alpha-1 is sold by research peptide suppliers operating under research-use-only labeling. Quality criteria include 99%+ HPLC-MS verified purity, per-lot Certificates of Analysis, mass spectrometry identity confirmation, and N-terminal acetylation verification. Browse the OPS Peptide Science catalog for verified research-grade Thymosin Alpha-1.

---

Thymosin Alpha-1 stands as one of the most clinically validated peptides in the modern research catalog — with decades of international therapeutic experience supplementing its pre-clinical research base. For researchers studying immune modulation, hepatitis biology, sepsis, immune recovery, or vaccine response research, Tα1 provides a research compound with an unusually robust evidence base.

For research-grade Thymosin Alpha-1 backed by per-lot Certificates of Analysis and full HPLC-MS purity documentation, browse the OPS Peptide Science catalog, visit the OPS Peptide Science homepage for the full product overview, or verify a specific lot using its COA code.

Author: Shane Straight, Principal Chemist, OPS Peptide Science
Reviewed: May 2026